New combo aims to wipe out prostate tumors before surgery

NCT ID NCT05498272

Ongoing Disease control Sponsor: Rana McKay, MD Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This phase 2 trial is testing whether giving the targeted drug olaparib (Lynparza) along with hormone therapy for 6 months before surgery can shrink or eliminate prostate cancer in men with high-risk disease and specific gene mutations. About 32 men will receive the treatment, then have their prostate removed to check for complete or near-complete tumor clearance. The goal is to see if this approach can improve outcomes for this aggressive cancer type.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Olaparib (Lynparza) plus a hormone therapy (LHRH agonist like goserelin, triptorelin, or leuprolide)
What this could lead to: If successful, this approach could shrink or eliminate prostate tumors before surgery, potentially improving long-term outcomes for men with certain genetic mutations.
What could go wrong: This is a small, early-phase trial with only 32 participants, so results may not apply to everyone. Olaparib can cause side effects like fatigue, nausea, and blood issues, and the combination with hormone therapy may increase risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRCA1 MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRCA1 MUTATION BRCA2 MUTATION HIGH-RISK CANCER PROSTATE CANCER PROSTATIC ADENOCARCINOMA

Contacts and locations

Locations

Columbia University Irving Medical Center

New York, New York, 10032, United States
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Baltimore, Maryland, 21287, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Penn Medicine Abramson Cancer Center

Philadelphia, Pennsylvania, 19104, United States
University of California San Diego - Moores Cancer Center

La Jolla, California, 92093, United States
University of Cincinnati

Cincinnati, Ohio, 45229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.